Some gain-of-function mutations on RBP4 promoter were reported to be associated with a higher risk of developing obesity or type 2 diabetes [15,16] while a non-coding mutation in RBP4 promoter is associated with dyslipidemia [17]. Here, RBP4 is linked to obesity due to melanocortin 4 receptor deficiency.